Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Alnylam Pharmaceuticals Inc. Revenue & Financial Statements
Alnylam Pharmaceuticals Inc. reported revenue of $3.7B for the fiscal year ended December 31, 2025, up 65.2% year over year, with net income of $313.7M and diluted EPS of $2.33.
- Company
- Alnylam Pharmaceuticals Inc. ALNY · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 844.3M | 1.0B | 1.8B | 2.2B | 3.7B |
| Cost of revenue | 115.0M | 140.2M | 268.2M | 306.5M | 677.2M |
| Gross profit | 729.3M | 897.2M | 1.6B | 1.9B | 3.0B |
| Operating income | (708.7M) | (785.1M) | (282.2M) | (176.9M) | 501.6M |
| Pretax income | (57.4M) | 21.6M | 16.8M | 194.6M | 304.9M |
| Net income | (842.5M) | (1.1B) | (419.0M) | (289.3M) | 313.7M |
| Diluted EPS | -7.20 | -9.30 | -3.52 | -2.18 | 2.33 |
| EBITDA | (671.9M) | (746.0M) | (230.6M) | (121.8M) | 556.4M |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 494.3M | 659.8M | 500.9M | 593.2M | 594.2M | 773.7M | 1.2B | 1.1B |
| Cost of revenue | 54.6M | 67.3M | 82.0M | 102.6M | 70.2M | 142.0M | 197.2M | 267.7M |
| Gross profit | 439.7M | 592.6M | 418.9M | 490.5M | 524.0M | 631.7M | 1.1B | 829.3M |
| Operating income | (43.4M) | 48.6M | (76.9M) | (105.2M) | 18.1M | (16.2M) | 368.0M | 131.7M |
| Pretax income | (63.6M) | (11.2M) | (108.7M) | (194.0M) | (41.6M) | (35.4M) | 239.0M | 161.1M |
| Net income | (69.5M) | (24.5M) | (101.8M) | (93.5M) | (60.5M) | (58.7M) | 259.3M | 186.4M |
| Diluted EPS | -0.52 | -0.13 | -0.87 | -0.65 | -0.44 | -0.51 | 1.84 | 1.38 |
| EBITDA | — | — | — | — | — | — | — | — |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 3.6B | 3.5B | 3.8B | 4.2B | 5.0B |
| Current assets | 2.8B | 2.7B | 3.0B | 3.3B | 4.1B |
| Cash & equivalents | 820.0M | 866.4M | 812.7M | 966.4M | 1.7B |
| Total liabilities | 3.1B | 3.7B | 4.1B | 4.2B | 4.2B |
| Current liabilities | 695.7M | 767.9M | 967.8M | 1.2B | 1.5B |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Stockholders’ equity | 588.2M | (158.2M) | (220.6M) | 67.1M | 789.2M |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | (641.7M) | (541.3M) | 104.2M | (8.3M) | 524.1M |
| Investing cash flow | (273.3M) | 169.4M | (336.4M) | (116.8M) | 436.3M |
| Financing cash flow | 1.2B | 425.8M | 172.1M | 294.2M | (305.2M) |
| Capital expenditure | 76.4M | 72.1M | 62.2M | 34.3M | 58.7M |
| Free cash flow | (718.1M) | (613.3M) | 41.9M | (42.6M) | 465.4M |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 165.7M | 230.6M | 221.7M | 272.1M | 348.2M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every ALNY filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.